67 related articles for article (PubMed ID: 27300169)
1. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
Nagata T; Shimada Y; Sekine S; Moriyama M; Hashimoto I; Matsui K; Okumura T; Hori T; Imura J; Tsukada K
Breast Cancer; 2017 Mar; 24(2):326-335. PubMed ID: 27300169
[TBL] [Abstract][Full Text] [Related]
2. Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells.
Wang Y; Xie Y; Niu Y; Song P; Liu Y; Burnett J; Yang Z; Sun D; Ran Y; Li Y; Sun L
Int J Med Sci; 2021; 18(8):1753-1759. PubMed ID: 33746592
[No Abstract] [Full Text] [Related]
3. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T
Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer.
Song Y; Zhao B; Xu Y; Ren X; Lin Y; Zhou L; Sun Q
BMC Cancer; 2020 Jun; 20(1):584. PubMed ID: 32571264
[TBL] [Abstract][Full Text] [Related]
5. Association between lincRNA expression and overall survival for patients with triple-negative breast cancer.
Ping J; Huang S; Wu J; Bao P; Su T; Gu K; Cai H; Guo X; Lipworth L; Blot WJ; Zheng W; Cai Q; Shu XO
Breast Cancer Res Treat; 2021 Apr; 186(3):769-777. PubMed ID: 33247368
[TBL] [Abstract][Full Text] [Related]
6. Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer.
Mulkearns-Hubert EE; Esakov Rhoades E; Ben-Salem S; Bharti R; Hajdari N; Johnson S; Myers A; Smith IN; Bandyopadhyay S; Eng C; Downs E; Lathia JD; Reizes O
Mol Cancer Ther; 2024 Jan; 23(1):56-67. PubMed ID: 37703580
[TBL] [Abstract][Full Text] [Related]
7. NANOG expression in human development and cancerogenesis.
Grubelnik G; Boštjančič E; Pavlič A; Kos M; Zidar N
Exp Biol Med (Maywood); 2020 Mar; 245(5):456-464. PubMed ID: 32041418
[TBL] [Abstract][Full Text] [Related]
8. COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis.
Majumder M; Xin X; Liu L; Tutunea-Fatan E; Rodriguez-Torres M; Vincent K; Postovit LM; Hess D; Lala PK
Stem Cells; 2016 Sep; 34(9):2290-305. PubMed ID: 27301070
[TBL] [Abstract][Full Text] [Related]
9. Krüppel-like factor 4 (KLF4): What we currently know.
Ghaleb AM; Yang VW
Gene; 2017 May; 611():27-37. PubMed ID: 28237823
[TBL] [Abstract][Full Text] [Related]
10. Expression of Krüppel-like factor 4 in breast cancer tissues and its effects on the proliferation of breast cancer MDA-MB-231 cells.
Song X; Xing YM; Wu W; Cheng GH; Xiao F; Jin G; Liu Y; Zhao X
Exp Ther Med; 2017 May; 13(5):2463-2467. PubMed ID: 28565864
[TBL] [Abstract][Full Text] [Related]
11. KLF4 inhibits colorectal cancer cell proliferation dependent on NDRG2 signaling.
Ma Y; Wu L; Liu X; Xu Y; Shi W; Liang Y; Yao L; Zheng J; Zhang J
Oncol Rep; 2017 Aug; 38(2):975-984. PubMed ID: 28656310
[TBL] [Abstract][Full Text] [Related]
12. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
13. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
14. Recent Discoveries on the Involvement of Krüppel-Like Factor 4 in the Most Common Cancer Types.
Taracha-Wisniewska A; Kotarba G; Dworkin S; Wilanowski T
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266506
[TBL] [Abstract][Full Text] [Related]
15. Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer.
Marks MP; Giménez CA; Isaja L; Vera MB; Borzone FR; Pereyra-Bonnet F; Romorini L; Videla-Richardson GA; Chasseing NA; Calvo JC; Vellón L
J Cancer Res Clin Oncol; 2024 Feb; 150(2):106. PubMed ID: 38418798
[TBL] [Abstract][Full Text] [Related]
16. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of combined cisplatin and
Abu Bakar NFAB; Yeo ZL; Hussin F; Madhavan P; Lim V; Jemon K; Prabhakaran P
J Taibah Univ Med Sci; 2023 Dec; 18(6):1220-1236. PubMed ID: 37250812
[TBL] [Abstract][Full Text] [Related]
18. Silencing Notch4 promotes tumorigenesis and inhibits metastasis of triple-negative breast cancer via Nanog and Cdc42.
Tian Y; Zhang P; Mou Y; Yang W; Zhang J; Li Q; Dou X
Cell Death Discov; 2023 May; 9(1):148. PubMed ID: 37149651
[TBL] [Abstract][Full Text] [Related]
19. KLF4 transcription factor in tumorigenesis.
He Z; He J; Xie K
Cell Death Discov; 2023 Apr; 9(1):118. PubMed ID: 37031197
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
